Comparative study on adverse reactions of levamlodipine versus amlodipine,nifedipine,and felodipine
Qiu Rong,Fu Yan,Zhao Xingshan,Gao Haiqing,Liu Kunshen,Zhao Tongbing,Li Shuren,Ren Ziwen,Hua Qi
DOI: https://doi.org/10.3969/j.issn.1008-5734.2009.05.003
2009-01-01
Abstract:Objective:To compare the differences in edema and other adverse reactions of levamlodipine versus amlodipine,nifedipine,and felodipine. Methods:A multicentre,randomized,open-label,self-control study was performed. Form June 2008 to March 2009,83 patients with mild-to-moderate primary hypertension,who experienced edema after receiving amlodipine (38 cases),nifedipine (30 cases),and felodipine (15 cases),were enrolled in the study. All above-mentioned medications were discontinued one week,then levamlodipine 2.5~5.0mg/d for 8 weeks was given. The observations and comparisons before and after levamlodipine treatment included:the severity of edema and other adverse reactions; the values of blood pressure,heart rate,and body weight; the results of routine blood tests and biochemical blood tests. Results:The severity of pitting edema at insteps was (2.69±1.21)mm one week before starting levamlodipine treatment and (1.63±1.35)mm and (1.74±1.90)mm after 4 and 8 weeks of treatment,respectively; the difference between one week before starting treatment and after 4 weeks of treatment was statistically significant (P< 0.05). The calf circumference 1 and calf circumference 2 were respectively (37.73±2.48)cm and (35.41±2.85)cm one week before starting treatment and (37.18±2.50)cm and (34.73±2.96)cm after 8 weeks of treatment; the differences were statistically significant (P< 0.05,P< 0.01). The ankle circumference were (23.47±2.19)cm 1 week before starting treatment and (22.83±2.09)cm after 8 weeks of treatment; the difference was statistically significant (P< 0.01). The incidence of facial flushing was 15.7% one week before starting treatment and 7.3%,2.5%,and 1.3% after 2,4,and 8 weeks of treatment,respectively. The incidence of dizziness was 4.8% one week before starting treatment and 2.4%,0,and 1.3% after 2,4,and 8 weeks of treatment. The blood pressure was (140.59±12.92)/(86.76±9.63) mm Hg before starting treatment and (125.76±8.53)/(77.84±6.46)mm Hg after 8 weeks of treatment,and heart rate was (70.93±8.30)beats/min before starting treatment and (69.17±6.52) beats/min after 8 weeks of treatment,respectively; the differences were statistically significant (P< 0.001,P< 0.05). Red blood cell count and hemoglobin level were (4.45±0.60)×1012/L and (131.22±14.95)g/L before starting treatment and (4.66±0.62)×1012/L and (138.09±17.46)g/L after 8 weeks of treatment,respectively; the differences were statistically significant (P< 0.05,P<0.01). No statistically significant difference in the indices of body weight,routine blood tests,and biochemical blood tests was found between before treatment and after treatment(all P> 0.05). Conclusion:levamlodipine is a relatively safe agent for treatment of hypertension,compared with amlodipine,nifedipine,and felodipine.